205 related articles for article (PubMed ID: 22156453)
21. The Neuroprotective Activities of the Novel Multi-Target Iron-Chelators in Models of Alzheimer's Disease, Amyotrophic Lateral Sclerosis and Aging.
Kupershmidt L; Youdim MBH
Cells; 2023 Feb; 12(5):. PubMed ID: 36899898
[TBL] [Abstract][Full Text] [Related]
22. Up-regulation of hypoxia-inducible factor (HIF)-1α and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30.
Avramovich-Tirosh Y; Bar-Am O; Amit T; Youdim MB; Weinreb O
Curr Alzheimer Res; 2010 Jun; 7(4):300-6. PubMed ID: 20043814
[TBL] [Abstract][Full Text] [Related]
23. Statins: multiple neuroprotective mechanisms in neurodegenerative diseases.
Wang Q; Yan J; Chen X; Li J; Yang Y; Weng J; Deng C; Yenari MA
Exp Neurol; 2011 Jul; 230(1):27-34. PubMed ID: 20406638
[TBL] [Abstract][Full Text] [Related]
24. Hypoxia-inducible factor 1: a new hope to counteract neurodegeneration?
Correia SC; Moreira PI
J Neurochem; 2010 Jan; 112(1):1-12. PubMed ID: 19845827
[TBL] [Abstract][Full Text] [Related]
25. A novel approach of proteomics and transcriptomics to study the mechanism of action of the antioxidant-iron chelator green tea polyphenol (-)-epigallocatechin-3-gallate.
Weinreb O; Amit T; Youdim MB
Free Radic Biol Med; 2007 Aug; 43(4):546-56. PubMed ID: 17640565
[TBL] [Abstract][Full Text] [Related]
26. Neurodegenerative diseases and therapeutic strategies using iron chelators.
Ward RJ; Dexter DT; Crichton RR
J Trace Elem Med Biol; 2015; 31():267-73. PubMed ID: 25716300
[TBL] [Abstract][Full Text] [Related]
27. The transition metals copper and iron in neurodegenerative diseases.
Rivera-Mancía S; Pérez-Neri I; Ríos C; Tristán-López L; Rivera-Espinosa L; Montes S
Chem Biol Interact; 2010 Jul; 186(2):184-99. PubMed ID: 20399203
[TBL] [Abstract][Full Text] [Related]
28. Cellular redox status regulates hypoxia inducible factor-1 activity. Role in tumour development.
Martínez-Sánchez G; Giuliani A
J Exp Clin Cancer Res; 2007 Mar; 26(1):39-50. PubMed ID: 17550131
[TBL] [Abstract][Full Text] [Related]
29. Iron: a new target for pharmacological intervention in neurodegenerative diseases.
Whitnall M; Richardson DR
Semin Pediatr Neurol; 2006 Sep; 13(3):186-97. PubMed ID: 17101458
[TBL] [Abstract][Full Text] [Related]
30. Synthesis, physical-chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimer's disease.
Gaeta A; Molina-Holgado F; Kong XL; Salvage S; Fakih S; Francis PT; Williams RJ; Hider RC
Bioorg Med Chem; 2011 Feb; 19(3):1285-97. PubMed ID: 21236688
[TBL] [Abstract][Full Text] [Related]
31. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases.
Weinreb O; Mandel S; Amit T; Youdim MB
J Nutr Biochem; 2004 Sep; 15(9):506-16. PubMed ID: 15350981
[TBL] [Abstract][Full Text] [Related]
32. Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders.
Mandel S; Amit T; Reznichenko L; Weinreb O; Youdim MB
Mol Nutr Food Res; 2006 Feb; 50(2):229-34. PubMed ID: 16470637
[TBL] [Abstract][Full Text] [Related]
33. Defective HIF signaling pathway and brain response to hypoxia in neurodegenerative diseases: not an "iffy" question!
Correia SC; Carvalho C; Cardoso S; Santos RX; Plácido AI; Candeias E; Duarte AI; Moreira PI
Curr Pharm Des; 2013; 19(38):6809-22. PubMed ID: 23530518
[TBL] [Abstract][Full Text] [Related]
34. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil.
Youdim MB; Amit T; Bar-Am O; Weinreb O; Yogev-Falach M
Neurotox Res; 2006 Dec; 10(3-4):181-92. PubMed ID: 17197368
[TBL] [Abstract][Full Text] [Related]
35. M30, a brain permeable multitarget neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models.
Youdim MB
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S151-4. PubMed ID: 22166418
[TBL] [Abstract][Full Text] [Related]
36. A Novel iron-chelating derivative of the neuroprotective peptide NAPVSIPQ shows superior antioxidant and antineurodegenerative capabilities.
Blat D; Weiner L; Youdim MB; Fridkin M
J Med Chem; 2008 Jan; 51(1):126-34. PubMed ID: 18078312
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease.
Avramovich-Tirosh Y; Amit T; Bar-Am O; Zheng H; Fridkin M; Youdim MB
J Neurochem; 2007 Jan; 100(2):490-502. PubMed ID: 17144902
[TBL] [Abstract][Full Text] [Related]
38. Green tea catechins as brain-permeable, non toxic iron chelators to "iron out iron" from the brain.
Mandel S; Weinreb O; Reznichenko L; Kalfon L; Amit T
J Neural Transm Suppl; 2006; (71):249-57. PubMed ID: 17447435
[TBL] [Abstract][Full Text] [Related]
39. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.
Mandel S; Weinreb O; Amit T; Youdim MB
Brain Res Brain Res Rev; 2005 Apr; 48(2):379-87. PubMed ID: 15850677
[TBL] [Abstract][Full Text] [Related]
40. A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer's and Parkinson's diseases.
Singh YP; Pandey A; Vishwakarma S; Modi G
Mol Divers; 2019 May; 23(2):509-526. PubMed ID: 30293116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
